Skip to main content

Table 7 Estimated costs and cost-effectiveness ratios of inhaled oxytocin introduction in each setting from a societal perspective and over a lifetime horizon, 3% discount rate

From: Cost-effectiveness of inhaled oxytocin for prevention of postpartum haemorrhage: a modelling study applied to two high burden settings

 

Bangladesh

Ethiopia

Status quo

Intervention

Incremental

Status quo

Intervention

Incremental

Costs, $000

Intervention start-up costsa

 

955

955

 

1308

1308

On-going PPH preventionb

783

985

202

840

1108

268

PPH treatment

52,479

50,606

− 1873

31,141

31,007

− 134

Total costs

53,262

52,546

− 716

31,981

33,423

1443

ICERs

$ per PPH case averted

 

Cost-saving

  

464

 

$ per maternal death averted

 

Cost-saving

  

47,557

 

$ per maternal life year saved

 

Cost-saving

  

1880

 

$ per maternal and child life year saved

 

Cost-saving

  

1005

 

ICERs (ongoing costs only)

$ per PPH case averted

 

Cost-saving

  

43

 

$ per maternal death averted

 

Cost-saving

  

4435

 

$ per maternal life year saved

 

Cost-saving

  

175

 

$ per maternal and child life year saved

 

Cost-saving

  

94

 
  1. Societal costs include public and private sector costs, and household medical and direct non-medical out of pocket costs in public and private sectors
  2. ICER incremental cost-effectiveness ratio, PPH postpartum haemorrhage
  3. aTraining and advocacy costs
  4. bCommodity (uterotonics), disposal and wastage costs